Statistics on Biotechnology Use  
Total Sectors
Biotechnology indicators by execution sector.
Unidades: Specified in each variable

,Total,Companies,Public Administration,Higher Education,NPPI,
Units carrying out R&D in Biotechnology,1.636,113,68,1.444,11,
% Units by type of biotechnology used: Genetic Code,37,2,87,6,94,1,30,7,27,3,
% Units by type of biotechnology used: Functional Units,43,5,86,7,95,6,37,6,54,5,
% Units by type of biotechnology used: Cell and Tissue Culture and Engineering,27,6,72,6,80,9,21,3,63,6,
% Units by type of biotechnology used: Bioprocesses,53,6,65,5,91,2,50,9,54,5,
% Units by type of biotechnology used: Subcellular Organisms,13,9,55,8,64,7,8,1,36,4,
% Units by type of biotechnology used: Bioinformatics,28,7,71,7,83,8,22,6,36,4,
% Units by type of biotechnology used: Nanobiotechnology,15,5,53,1,73,5,9,8,18,2,
% Units by type of biotechnology used: Other,15,7,7,1,7,3,16,9,9,1,
Units in which biotechnology activities are: Main and/or exclusive,676,35,5,629,7,
Units in which biotechnology activities are: A secondary business line,347,36,47,262,2,
Units in which biotechnology activities are: A necessary tool for production,613,42,16,553,2,
% Units by final application areas of biotechnology use: Human Health,48,7,76,1,92,7,44,3,72,7,
% Units by final application areas of biotechnology use: Animal Health and Aquaculture,17,8,18,6,61,8,15,8,9,1,
% Units by final application areas of biotechnology use: Food Products,32,4,26,6,82,3,30,7,0,
% Units by final application areas of biotechnology use: Agriculture and Forestry,26,4,21,2,67,7,24,9,18,2,
% Units by final application areas of biotechnology use: Environment,19,8,23,9,75,16,9,9,1,
% Units by final application areas of biotechnology use: Industry,15,2,18,6,66,2,12,6,9,1,
R&D personnel in Biotechnology (PP),50.084,15.563,16.597,17.743,181,
R&D personnel in Biotechnology (PP): Research personnel,32.396,9.798,13.026,9.445,127,
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel,17.688,5.765,3.571,8.298,54,
R&D personnel in Biotechnology (PP). Women,28.401,9.804,8.578,9.907,112,
R&D personnel in Biotechnology (PP). Women: Research personnel,17.461,5.851,6.435,5.104,71,
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel,10.939,3.953,2.143,4.802,41,
R&D personnel in Biotechnology (FTE),35.301,2,11.442,1,10.721,9,12.993,4,143,8,
R&D personnel in Biotechnology (FTE): Research personnel,22.324,6,6.766,8,8.386,7,7.069,9,101,2,
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel,12.976,7,4.675,3,2.335,2,5.923,6,42,6,
R&D personnel in Biotechnology (FTE). Women,20.474,8,7.280,8,5.633,9,7.471,8,88,3,
R&D personnel in Biotechnology (FTE). Women: Research personnel,12.176,5,4.080,5,4.171,9,3.870,1,54,
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel,8.298,2,3.200,3,1.462,3.601,6,34,3,
Expenditure on internal R&D in Biotechnology (thousands of euros),2.565.367,775.164,554.906,1.223.801,11.496,
1) By type of expenditure: Current expenditure,2.359.528,727.099,513.043,1.108.189,11.197,
1.1) Labour expenditure of research personnel,950.162,267.235,318.977,360.922,3.027,
1.2) Labour expenditure of technical and auxiliary personnel,421.784,128.800,71.268,220.540,1.176,
1.3) Other current expenditure,987.583,331.063,122.798,526.727,6.994,
2) By type of expenditure: Capital expenditure,205.839,48.066,41.862,115.612,299,
2.1) Land and buildings,30.577,6.521,7.162,16.843,52,
2.2) Equipment and tools,136.544,39.416,33.362,63.527,239,
2.3) Acquisition of specific R&D software,7.117,1.945,1.211,3.959,3,
2.4) Other R&D-specific IP products,31.601,184,128,31.284,5,
1.1) By origin of funds: Own funds,1.030.214,78.546,90.048,860.603,1.016,
1.2) By origin of funds: Funds from the Business sector,277.770,115.144,27.808,128.002,6.816,
1.3) By origin of funds: Funds from the Public Administration sector,951.439,458.700,372.119,119.498,1.122,
1.4) By origin of funds: Funds from the Higher Education sector,4.307,1.537,2.122,647,0,
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector,52.107,28.686,9.445,12.986,990,
1.6) By origin of funds: Funds from the rest of the world,249.530,92.551,53.363,102.065,1.551,
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros),171.660,35.006,13.038,123.396,220,
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain,131.863,30.282,12.385,88.985,212,
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world,39.797,4.725,653,34.412,8,
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to capital,41,8,57,5,52,9,39,8,72,7,
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information,14,8,8,8,14,7,15,3,9,1,
% Units that consider the following obstacles to the development of biotechnologies as very important: Access to human resources,24,5,46,36,8,22,3,18,2,
% Units that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain,13,8,23,35,3,12,1,9,1,
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets,19,28,3,44,1,17,1,27,3,
% Units that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels,19,4,28,3,38,2,17,8,18,2,
% Units that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception,15,3,10,6,10,3,16,9,1,
% Units that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements,41,3,40,7,39,7,41,4,36,4,
% Units that consider the following obstacles to the development of biotechnologies as very important: Time/cost,51,2,62,8,51,5,50,2,63,6,
% Units that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting,20,19,5,19,1,20,1,18,2,
Notas:
Data referring to all companies and organisations that carry out internal R&D in Biotechnology.
 2) ' .'= numeric data equal to zero not resulting from rounding
 3) FTE: Full-Time Equivalence
Fuente: National Statistics Institute